Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Enlivex Therapeutics Ltd (ENLV)

Enlivex Therapeutics Ltd (ENLV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 77,170
  • Shares Outstanding, K 10,114
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,240 K
  • 60-Month Beta 1.55
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.46

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.25 +22.08%
on 11/06/19
9.24 -17.42%
on 11/04/19
-0.85 (-10.02%)
since 10/21/19
3-Month
6.25 +22.08%
on 11/06/19
44.90 -83.01%
on 09/23/19
-20.31 (-72.69%)
since 08/21/19
52-Week
6.16 +23.86%
on 12/31/18
44.90 -83.01%
on 09/23/19
-3.25 (-29.87%)
since 11/21/18

Most Recent Stories

More News
Enlivex Therapeutics Ltd. Announces Withdrawal of Proposed Offering of Ordinary Shares

Enlivex Therapeutics Ltd. ("Enlivex" or the "Company") (NASDAQ: ENLV) today announced that it has withdrawn its previously announced proposed underwritten public offering of ordinary shares due to market...

ENLV : 7.63 (-7.85%)
Enlivex Therapeutics Ltd. Announces Proposed Offering of Ordinary Shares

Enlivex Therapeutics Ltd. ("Enlivex" or the "Company") (NASDAQ:

ENLV : 7.63 (-7.85%)
Enlivex Therapeutics Completes Recruitment In Phase Ib Trial Evaluating Safety And Efficacy Of Universal Off-The-Shelf Allocetra In Patients With Severe Sepsis

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today reported completion of patient recruitment into the Company's Phase Ib clinical trial in patients with severe sepsis....

ENLV : 7.63 (-7.85%)
Enlivex Therapeutics To Present At The 10th Annual Jefferies 2019 London Healthcare Conference

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that company management will make a corporate presentation and host 1x1 meetings at the 10th Annual Jefferies...

ENLV : 7.63 (-7.85%)
Company News For Nov 5, 2019

Companies In The News Are: WMGI, ENLV, CRNT, UAA

WMGI : 29.49 (-0.07%)
UAA : 16.99 (unch)
CRNT : 1.88 (+5.62%)
ENLV : 7.63 (-7.85%)
Enlivex Therapeutics Announces Positive Interim Safety and Efficacy Data From Ongoing Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced positive interim efficacy data from the Company's ongoing Phase Ib clinical trial in patients with severe...

ENLV : 7.63 (-7.85%)
Enlivex Announces Appointment of New Chief Executive Officer

Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced the appointment of Dr. Oren Hershkovitz as Chief Executive Officer, effective November 16, 2019. Dr. Hershkovitz served...

ENLV : 7.63 (-7.85%)
OPK : 1.60 (+1.91%)
Preclinical Data Indicating Allocetra-OTS As Potential Therapy For Prevention Of Organ Failure And Mortality Associated with Severe Sepsis Selected For Presentation At The XVIIIth Congress Of the European and Int'l Shock Societies

Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, today announced today that the European and Int'l Shock Societies selected, for an oral presentation, "Pathogen- and damage-associated...

ENLV : 7.63 (-7.85%)
European Patent Office Grants New Patent Covering Enlivex's Allocetra(TM) Immunotherapy Treatment

Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the European Patent Office granted a new patent (#EP 2 929 015 B1) covering ALLOCETRA, the company's immunotherapy...

ENLV : 7.63 (-7.85%)
Data On Combination Of Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Selected For Presentation At The European Molecular Biology Organization's 2019 Cell Death in Immunity and Inflammation Workshop

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the European Molecular Biology Organization (EMBO) selected, for a scientific presentation, the poster:...

ENLV : 7.63 (-7.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

The current trending strength of the market is Average.

See More Share

Trade ENLV with:

Business Summary

Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome)...

See More

Key Turning Points

2nd Resistance Point 8.62
1st Resistance Point 8.12
Last Price 7.63
1st Support Level 7.36
2nd Support Level 7.10

See More

52-Week High 44.90
Fibonacci 61.8% 30.10
Fibonacci 50% 25.53
Fibonacci 38.2% 20.96
Last Price 7.63
52-Week Low 6.16

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar